Blogger: Signe Åsberg
PhD student at CEMIR
This blog post was originally posted on Åsberg’s science blog Furby in the lab.
Let me give you a list of all the aspects of my job as a PhD student that I love. It really is a great ride but also incredibly difficult and I find myself easily sucked into the dark thoughts of how this will never work out, I’m the worst scientist in history and my project is not worth doing. I think it is time to will myself out of the dark places and focus on what I enjoy:
– First of all I get to think. A lot. Almost all the time, every day. I think, ponder, question, wonder. It’s a privilege.
– I get to look closely at microscopic organisms. I love looking at things. There’s just nothing better than looking at something amazing with your own eyes. I get to see cells, bacteria and even proteins. Or I get to see the light that the fluorophores I attached to those proteins emit when I excite them.
– This brings me to attaching fluorophores to proteins. I’m excited about that. I get to glue molecules together!
Blogger: Guro Stødle and Line Tangerås
PhD students, CEMIR
In the human body, infections (caused by bacteria or virus) and tissue injury may set off an inflammatory response, in which immune cells, blood vessels, proteins and other mediators work together to eliminate the threat and repair the damage.
Pregnancy is a delicate setting where the mother and fetus must adapt properly to each other to coexist, and an inflammatory response can disturb this delicate balance and cause complications. This is seen in preeclampsia, a potentially severe inflammatory pregnancy disorder threatening both the mother and fetus.
In preeclampsia, inflammation in the placenta contributes to poor placental development, later leading to systemic inflammation in the mother, manifesting as high blood pressure and protein in the mother’s urine.
Professor Bruce Beutler.
Photo: Holger Motzkau / Wikimedia Commons
The Board of the Norwegian University of Science and Technology, NTNU, has decided to award Professor Bruce Beutler an honorary doctorate, the degree of doctor honoris causa. The appointment of Beutler recognizes his significant contributions to understanding how innate immune cell receptors regulate inflammatory responses.
Butler was awarded the Nobel Prize in Physiology or Medicine in 2011 for his research on innate immunity. He shared the prize with med Jules A. Hoffmann and Ralph M. Steinman.
Bruce Beutler’s groundbreaking discoveries about sensors in our innate immune system that recognize bacteria have led to an explosion of research on this theme. Beutler’s work has greatly inspired scientists at NTNU’s Centre of Molecular Inflammation Research (CEMIR) working in the same field as him.
Egil Lien wearing safety gear at the lab.
It took almost six months for Egil Lien to get permission from the Federal Bureau of Investigation in the US to study the plague bacteria that, in its time, killed half of Norway’s population. Now, an antibiotic-resistant strain of the bacteria has been found.
As the bacteria responsible for killing a large part of Europe’s population during the Black Death, the plague bacteria Yersinia pestis has a long kill list on its conscience.
Read more at Gemini.no
Bloggers: May-Britt Tessem and Morten Beck Rye
As we speak there are no accurate methods to diagnose potentially dangerous prostate cancer in an early stage of cancer.
From a pathologist’s point of view, aggressive cancers look totally similar to harmless subtypes in the beginning of development. As a consequence, the patients will be at high risk of overtreatment in the majority of cases where prostate cancer is detected. We urgently need new tools and markers to sort out the potentially dangerous types of prostate cancer from the non-dangerous in early disease. Most importantly, this will save the patients from reduced quality of life due to unnecessary surgical interventions, and also be economically beneficial for society.
Filed under Cancer, Research
Blogger: Bjørn Gustafsson
Dean of Research, The Faculty of Medicine, NTNU
Last week one of our research groups, led by Professor Duan Chen, published a comprehensive scientific study showing promising results in treating gastric cancer, by blocking the tumor nerve supply. The article was published in the prestigious journal Science Translational Medicine.
From left: The Knowledge Center, Chun-Mei Zhao, Gøran T. Andersen (in the background), Duan Chen bottom right (Photo: Helsebygg/Geir Mogen)
The term “translational medicine” involves transferring new knowledge from basic research on for instance cell culture or animal models to practical use in patient care; also coined with the term “from bench-to-bedside”.
The Centre of Molecular Inflammation Research, CEMIR, will hold the annual scientific seminar on inflammation research on September 4, 2014.
Speakers include the renowned professors
Clockwise from top left: Alan Aderem, Göran Hansson, Stefanie Vogel and Douglas Golenbock
The invited speakers will relate to the inflammation research area in different ways.
The seminar is open for all and you do not need to register in avance to participate.
CEMIR was established in 2013 as a Centre of Excellence appointed by the Research Council of Norway. The vision of CEMIR is to lay the foundation for identifying new therapeutic targets and developing new diagnostic tools for inflammatory diseases through an integrated 10-year programme of research and research training in molecular innate immune responses. CEMIR is hosted by the Faculty of Medicine at the Norwegian University of Science and Technology (NTNU).
Please find the full seminar program and see the titles of the talks here: CEMIR seminar 2014 programme (pdf)
Gøran Andersen and Duan Chen. (Foto: Geir Mogen)
In laboratory tests at The Faculty of medicine, NTNU, Botox proved highly effective at suppressing gastric cancer in mice.
The promising results have led to the launch of an early clinical trial involving human patients with stomach cancer in Norway and St. Olavs Hospital.
Blogger: Ørnulf Paulsen
Ørnulf Paulsen is a PhD student at European Palliative Care Research Centre, NTNU, and Senior Consultant in palliative medicine at Telemark Hospital
Until now, clinicians have assumed that corticosteroids effectively relieve pain in cancer patients. A new study shows that this is not the case.
The results from our study have recently been published in the acknowledged Journal of Clinical Oncology.
Placebo shows same effect
Corticosteroids are widely used for the most advanced cancer patients, and pain treatment is one of the indications. The pain relieving effect, however, has never been documented in research results. Our study showed that the drug had no pain relieving effect for the cancer patients who participated in the study.